Padlock Therapeutics is a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases. The company leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. Padlock was founded by scientists at The Scripps Research Institute in conjunction with Atlas Venture. Padlock's Series A investors include Atlas Venture, Johnson & Johnson Innovation - JJDC, Inc., MS Ventures, and Index Ventures.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/18/14 | $23,000,000 | Series A |
Atlas Venture Index Ventures Johnson & Johnson Innovation MS Ventures | undisclosed |
